Abstract
Pharmacological properties of 6, 6, 9-trimethyl-9-[3, 3, 1]non-3β-yl α, α-di(2-thienyl)glycolate hydrochloride monohydrate (PG-501) were examined as an anti-parkinsonian agent. PG-501 was found to have pronounced anti-acetylcholine, anti-tremorine-induced tremor, anti-physostigmine-induced death, anti-haloperidol-induced parkinsonism and anti-EEG arousal activities. PG-501 was also found to have greater dissociation between contral and peripheral anticholinergic activities. These results suggest that PG-501 has great benefit in the treatment of parkinsonism, especially in the prevention of undesirable side-effects.
